GlycoMimetics Inc

NASDAQ:GLYCUnited States

GlycoMimetics, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of glycomimetic drugs. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer, and infection. Its drug candidates include Uproleselan, GMI-1359, GMI-1687, and Galectin Antagonists. It is developing Uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). Its GMI-1359 targets both E-selectin and a chemokine receptor known as CXCR4. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. It has designed various small-molecule glycomimetic antagonists of galectin-3, including a product candidate that has demonstrated oral bioavailability.

Contact Information

Headquarters

9708 Medical Center DriveROCKVILLE, MD, United States 20850

Phone

240-243-1201

Fax

240-243-1018

Executives

Independent Chairman of the Board

Timothy Pearson

President, Chief Executive Officer, Director

Harout Semerjian

Co-Founder, Senior Vice President of Research, Chief Scientific Officer

John Magnani

Chief Financial Officer, Senior Vice President - Finance

Brian Hahn

Senior Vice President - Strategy and Corporate Development, Chief Business Officer

Armand Girard